Literature DB >> 23303795

[The role of whole brain radiation therapy for brain metastases].

Delphine Antoni1, Georges Noël, Françoise Mornex.   

Abstract

Brain metastases are the leading cause of intracranial malignancy and a major cause of mortality and morbidity. From 20 to 40% of cancer patients develop brain metastases. The irradiation of the whole brain remains the most commonly undertaken treatment, but should be discussed in relation to other therapeutic alternatives such as stereotactic radiotherapy or the use of new chemotherapy drugs. Its use according to pathology should be discussed. It can lead to a long-term neurocognitive toxicity that should be evaluated more precisely. This literature review aims to highlight the role of whole-brain radiotherapy used alone or in combination with other treatments.

Entities:  

Keywords:  brain metastasis; whole brain radiation therapy

Mesh:

Substances:

Year:  2013        PMID: 23303795     DOI: 10.1684/bdc.2012.1675

Source DB:  PubMed          Journal:  Bull Cancer        ISSN: 0007-4551            Impact factor:   1.276


  5 in total

1.  Local recurrence and cerebral progression-free survival after multiple sessions of stereotactic radiotherapy of brain metastases: a retrospective study of 184 patients : Statistical analysis.

Authors:  Laure Kuntz; Clara Le Fèvre; Delphine Jarnet; Audrey Keller; Philippe Meyer; Caroline Bund; Isabelle Chambrelant; Delphine Antoni; Georges Noel
Journal:  Strahlenther Onkol       Date:  2022-03-16       Impact factor: 4.033

Review 2.  Current treatment options of brain metastases and outcomes in patients with malignant melanoma.

Authors:  Jadwiga Nowak-Sadzikowska; Tomasz Walasek; Jerzy Jakubowicz; Paweł Blecharz; Marian Reinfuss
Journal:  Rep Pract Oncol Radiother       Date:  2015-12-29

3.  Serum CA125 level predicts prognosis in patients with multiple brain metastases from non-small cell lung cancer before and after treatment of whole-brain radiotherapy.

Authors:  Yue-Can Zeng; Rong Wu; Si-Liang Wang; Feng Chi; Rui Xing; Wei-Song Cai; Guo-Liang Fan; Yu-Chen Fan; Wen-Zhao Zhong; Li-Na Wu; Xiao-Dong Chen; Huan-Huan Chen; Yu-Ping Xiao
Journal:  Med Oncol       Date:  2014-06-10       Impact factor: 3.064

4.  Phase II clinical trial of whole-brain irradiation plus three-dimensional conformal boost with concurrent topotecan for brain metastases from lung cancer.

Authors:  Xiao-Hui Ge; Qiang Lin; Xiao-Cang Ren; Yue-E Liu; Xue-Ji Chen; Dong-Ying Wang; Yong-Qiang Wang; Bin Cao; Zhi-Gang Li; Miao-Ling Liu
Journal:  Radiat Oncol       Date:  2013-10-14       Impact factor: 3.481

5.  Clinical investigation into the initial diagnosis and treatment of 539 patients with stage IV lung cancer.

Authors:  Qian Shao; Shanshan Liu; Wei Wang; Yingjie Zhang; Fengxiang Li; Jianbin Li
Journal:  Onco Targets Ther       Date:  2017-01-31       Impact factor: 4.147

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.